Papillary thyroid tumors: Diagnostic value of CD56 and Cytokeratin 19

##plugins.themes.academic_pro.article.main##

Alia Zehani
Amine Bani
Ines Chelly
Salsabil Rejaibi
Ghazi Besbes
Slim Haouet
Nidhameddine Kchir

Abstract

Introduction :
Noninvasive Follicular Thyroid Neoplasm With Papillary-like Nuclear Features (NIFTP) is a tumor composed exclusively of follicles lined by cells having nuclear characteristics of papillary carcinoma. Morphological diagnosis is often difficult especially in the cases in which these nuclear abnormalities are focal.
The aim of our study was to investigate the contribution of the immunohistochemical study with anti CD56 and anti cytokeratin 19 in the positive diagnosis of NIFTP.
Methods:
This is a diagnostive, retrospective study of 40 thyroid specimens including 15 NIFTP, 10 classical form papillary carcinoma (CPC) and 15 vesicular adenomas (AV), collected over a period of eighteen months (December 2013-May 2015).
Results:
Negativity with anti-CD56 was noted in 16 cases: 9 cases of NIFTP and 7 cases of CPC. A diffuse staining was noted in 14 cases of AV. Positivity with anti-Cytokeratin19 was noted in 38 cases: 14 NIFTP, 10 CPC and 14 AV. For the diagnosis of NIFTP, the sensitivity of CD56 was 60% and specificity of 100%. The sensitivity of the Cytokeratin 19 was 93,3 % and specificity of 33,3%.
Conclusions :
Considering the good sensitivity and specificity of the CD56, it is possible to apply immunohistochemistry for definitive diagnosis of NIFTP and to differentiate it from adenoma. The cytokeratin 19 does not have a big contribution to distinguish between benign and malignant lesions.

Keywords:

Papillary carcinoma; NIFTP; thyroid; immunohistochemistry; CD56; CK19

##plugins.themes.academic_pro.article.details##

References

  1. Nechifor-Boila A, Borda A, Sassolas G, Hafdi-Nejjari Z, Borson-Chazot F, Lifante JC, et al. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56. Pathol Res Pract. 2013; 209: 585‑92.
  2. Lam AK. Pathology of Endocrine Tumors Update: World Health Organization New Classification 2017-Other Thyroid Tumors. AJSP: Reviews & Reports 2017; 22: 209-16.
  3. El Demellawy D, Nasr AL, Babay S, Alowami S. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. Pathol Res Pract. 2009;205:303‑9.
  4. Shahebrahimi K, Madani SH, Fazaeli AR, Khazaei S, Kanani M, Keshavarz A. Diagnostic value of CD56 and nm23 markers in papillary thyroid carcinoma. Indian J Pathol Microbiol. 2013; 56:2‑5.
  5. Ceyran AB, Åženol S, Åžimşek BÇ, SağıroÄŸlu J, Aydın A. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin. Int J Clin Exp Pathol. 2015;8:3670-80.
  6. Guerra A, Marotta V, Deandrea M, Motta M, Limone PP, Caleo A, et al. BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma. Endocrine. 2013;44:165‑71.
  7. Wu G, Wang J, Zhou Z, Li T, Tang F. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: Improvement in the sensitivity or specificity? J Int Med Res. 2013;41:975‑83.
  8. Saleh HA, Jin B, Barnwell J, Alzohaili O. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol. 2010;5:9.
  9. Nakamura N, Erickson LA, Jin L, Kajita S, Zhang H, Qian X, et al. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma. Endocr Pathol. 2006;17:213-23.
  10. Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007;18:1‑7.
  11. Passler C, Prager G, Scheuba C, Niederle BE, Kaserer K, Zettinig G, et al. Follicular variant of papillary thyroid carcinoma: a long-term follow-up. Arch Surg. 2003;138: 1362‑6.
  12. Zidan J, Karen D, Stein M, Rosenblatt E, Basher W, Kuten A. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer. 2003;97:1181‑5.
  13. Berger N. Pathologie thyroidienne, parathyroidienne et surrénalienne. Montpellier: Sauramps medical; 2010.
  14. Basu S. Bilateral axillary and infrahilar nodal metastases in follicular variant of papillary thyroid carcinoma (transformed into poorly differentiated subtype) in the setting of elevated thyroglobulin and negative radioiodine scintigraphy. J Cancer Res Ther. 2016;12:423‑4.
  15. Yang J, Gong Y, Yan S, Shi Q, Zhu J, Li Z, et al. Comparison of the clinicopathological behavior of the follicular variant of papillary thyroid carcinoma and classical papillary thyroid carcinoma: A systematic review and meta-analysis. Mol Clin Oncol. 2015;3:753‑64.
  16. Yoon JH, Kim E-K, Youk JH, Moon HJ, Kwak JY. Better understanding in the differentiation of thyroid follicular adenoma, follicular carcinoma, and follicular variant of papillary carcinoma: a retrospective study. Int J Endocrinol. 2014;2014:321595.
  17. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LDR, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016; 2:1023-9.
  18. Elsheikh TM, Asa SL, Chan JKC, DeLellis RA, Heffess CS, LiVolsi VA, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol. 2008;130:736‑44.
  19. Nasr MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining. Mod Pathol. 2006;19:1631‑7.
  20. El Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol. 2008;3:5.
  21. Nechifor-Boilă A, Cătană R, Loghin A, Radu TG, Borda A. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential. Romanian J Morphol Embryol. 2014;55:49‑56.
  22. Zeromski J, Lawniczak M, Galbas K, Jenek R, Golusiński P. Expression of CD56/N-CAM antigen and some other adhesion molecules in various human endocrine glands. Folia Histochem Cytobiol. 1998;36:119‑25.
  23. DunÄ‘erović D, Lipkovski JM, BoriÄic I, Soldatović I, Božic V, Cvejić D, et al. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature. Diagn Pathol. 2015;10:196.
  24. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001;14:338‑42.
  25. Alshenawy HA. Utility of immunohistochemical markers in diagnosis of follicular cell derived thyroid lesions. Pathol Oncol Res. 2014;20:819‑28.